Pacific Biosciences sold select short‑read sequencing intellectual property and assets (including technology from Apton/Omniome Onso) to Illumina for $48.1 million, saying the move sharpens its focus on long‑read sequencing. PacBio will retain a non‑exclusive license to some purchased IP and reported net cash proceeds after obligations. PacBio framed the divestiture as strategic refocusing amid challenging macro conditions and prior pauses in short‑read platform development. Illumina gains additional short‑read technology that could complement its existing portfolio; the transaction also signals continued market consolidation between instrument and reagent providers across sequencing modalities.